During the past decade, TCA Cellular Therapy conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "TCA Cellular Therapy" are "Coronary Artery Disease" (3 trials), "Coronary Atherosclerosis" (3 trials), "Coronary Disease" (3 trials), "Coronary Arteriosclerosis" (2 trials) and "Coronary Ischemia" (2 trials). Many other conditions were trialed in "TCA Cellular Therapy" in a lesser frequency.

Most popular intervention types in "TCA Cellular Therapy" are "Biological" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "MESENDO" (4 trials), "Autologous bone marrow-derived mesenchymal stem cells." (1 trials), "Mesendo" (1 trials), "Placebo" (1 trials) and "autologous bone marrow-derived stem cells" (1 trials). Other intervention names were less common.

The vast majority of trials in "TCA Cellular Therapy" are 7 trials for "All" genders.

Currently, there are NaN active trials in "TCA Cellular Therapy". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in TCA Cellular Therapy, 3 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in TCA Cellular Therapy, 5 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".